Which hedge funds own DXCM? DEXCOM INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
13 of the hedge funds tracked by WhaleCreep disclosed a position in DXCM (DEXCOM INC) in their Q2 2026 13F filings, worth $1.2bn in total. The largest holder by portfolio weight is Avidity Partners at 1.1% of its book.
13tracked managers holding
0opened this quarter
0exited this quarter
Which hedge funds hold DXCM? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Avidity Partners | Q2 2026 | 1.1% | $6.7m | 100,000 | 11% | added |
| Baillie Gifford | Q2 2026 | 0.9% | $799.1m | 14,801,590 | -5% | reduced |
| Renaissance Technologies LLC | Q2 2026 | 0.2% | $109.8m | 1,630,796 | 3% | added |
| Suvretta Capital Management | Q2 2026 | 0.1% | $6.9m | 101,980 | 222% | added |
| Woodline Partners | Q2 2026 | 0.1% | $36.1m | 536,702 | 5% | added |
| Bridgewater Associates | Q2 2026 | 0.1% | $27.0m | 400,929 | 187% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $81.6m | 1,211,767 | -42% | reduced |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $2.2m | 32,813 | -33% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $35.9m | 532,804 | 681% | added |
| Point72 Asset Management LP | Q2 2026 | 0.0% | $19.0m | 282,840 | 10% | added |
| Millennium Management | Q2 2026 | 0.0% | $26.6m | 395,392 | -76% | reduced |
| Ancora Advisors | Q2 2026 | 0.0% | $65.7k | 976 | 354% | added |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $382.5k | 5,679 | -80% | reduced |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Caxton Associates | Q4 2024 | 0.7% |
How has hedge fund ownership of DXCM changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 13 | $1.2bn |
| Q1 2026 | 13 | $2.2bn |
| Q4 2025 | 9 | $576.4m |
| Q3 2025 | 11 | $1.8bn |
| Q2 2025 | 9 | $1.6bn |
| Q1 2025 | 10 | $1.4bn |
| Q4 2024 | 11 | $2.1bn |
| Q3 2024 | 8 | $1.3bn |
| Q2 2024 | 12 | $5.6bn |
| Q1 2024 | 13 | $3.2bn |
| Q4 2023 | 15 | $3.4bn |
| Q3 2023 | 13 | $2.6bn |
| Q2 2023 | 14 | $3.1bn |
| Q1 2023 | 14 | $3.1bn |
| Q4 2022 | 13 | $3.2bn |
| Q3 2022 | 13 | $2.6bn |
Counts every tracked manager that disclosed DXCM in that quarter's filing, including managers that have since stopped filing.